SOLUBLE ENDOGLIN AS AN EARLY PREDICTION MARKER OF INTRAUTERINE GROWTH RETARDATION

Authors:

Abstract:

High levels of circulating endoglin contribute to the development of endothelial dysfunction, which underlies the pathogenesis of intrauterine growth retardation and can be used as a prognostic marker for the development of this pathology. We collected serum from pregnant women with intrauterine growth retardation (n-41) initially at diagnosis and before delivery, and pregnant women with physiological pregnancy (n-8), using enzyme-linked immunosorbent assay to test soluble endoglin levels. It was found that the level of soluble endoglin concentration was 7.2±0.2 at the initial examination and 9.5±0.1 at the repeated examination in women who gave birth to low birth weight children with fetal developmental delay and constitutionally small children, while the level of this factor in women in the comparison group was 3.7±0.3. It was found that the level of soluble endoglin concentration was significantly higher in women who gave birth to children with intrauterine growth retardation than the level of this factor in women in the comparison group, which is highly informative to use its prognostic value.

Keywords:

soluble endoglin fetal growth retardation gestational age low birth weight fetus

References:

1. Alahakoon TI, Zhang W, Trudinger BJ, Lee VW. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med. 2014 Dec;27(18):1854–9. DOI: 10.3109/14767058.2014.880882.
2. Brownfoot F, Kaitu'u-Lino T, Beard S, Tong S, Hannan N. sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies? Pregnancy Hypertens. 2017 Oct;10:18–21. DOI: 10.1016/j.preghy.2017.07.138.
3. Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(8):1214–28. DOI: 10.3109/14767058.2015.1048431.
4. Gaccioli F, Aye ILMH, Sovio U, Charnock-Jones DS, Smith GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2018 Feb;218(2S):725–737. DOI: 10.1016/j.ajog.2017.12.002.
5. Lawera A, Tong Z, Thorikay M, Redgrave RE, Cai J, Van Dinther M et al. Role of soluble endoglin in BMP9 signaling. Proc Natl Acad Sci USA. 2019 Sep 3;116(36):17800–17808. DOI: 10.1073/pnas.1816661116.
6. Leaños-Miranda A, Navarro-Romero CS, Sillas-Pardo LJ, Ramírez-Valenzuela KL, Isordia-Salas I, Jiménez-Trejo LM. Soluble Endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. Hypertension. 2019 Oct;74(4):991–997. doi: 10.1161/hypertensionaha.119.13348.
7. Liu Z, Lebrin F, Maring JA, van den Driesche S, van der Brink S, van Dinther M et al. Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis. PLoS One. 2014 Jan 28;9(1):e86273. DOI: 10.1371/journal.pone.0086273.
8. Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor-alpha receptors in different clinical manifestations of preeclampsia. PLoS One. 2014 May 22;9(5):e97632. doi: 10.1371/journal.pone.0097632.
9. Raia-Barjat T, Prieux C, Gris J-C, Chapelle C, Laporte S, Chauleur C. Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: angiopred study. J Matern Fetal Neonatal Med. 2019 Jan;32(2):248–257. DOI: 10.1080/14767058.2017.1378325.
10. Sharabi-Nov A, Kumar K, Vodušek VF, Sršen TP, Tul N, Fabjan T et al. Establishing a differential marker profile for pregnancy complications near delivery. Fetal Diagn Ther. 2020;47(6):471–484. DOI: 10.1159/000502177.
11. Sherin UD, Chu A. Intrauterine Growth Restriction: Hungry for an Answer. Physiology (Bethesda). 2016 Mar;31(2):131–46. DOI: 10.1152/physiol.00033.2015.
12. Torchin H, Combarel D, Aubelle M-S, Lopez C, Dubray L, El Ayoubi M et al. Association of serum angiogenic factors with bronchopulmonary dysplasia. The angiodys cohort study. Pregnancy Hypertens. 2019 Oct;18:82–87. DOI: 10.1016/j.preghy.2019.09.015.

Publication:

«World of Medicine and Biology» Vol. 17 No. 78 (2021) , с. 41-45
УДК 616.33-06-07

DOI:

https://doi.org/10.26724/2079-8334-2021-4-78-41-45